Sekisui Diagnostics announced its plans to invest US$ 18.6 million (£14.4 million) in biopharma CDMO business to expand cGMP microbial capacity located at its existing site in Maidstone.
The new cGMP certified microbial fermentation and purification suites are expected to accommodate production scales up to 1,000L, complementing its existing capabilities that range from 20L to 5,000L fermentation scale.
The new facility and cGMP upgrades will help Sekisui take on drug substance contract manufacturing for its programs entering clinical trial phase.
The new investment made in cGMP capacity expansion will better serve the biopharma customers with much needed cGMP microbial CDMO production capacity.
The project is expected to be completed by the second half of 2022.
|US$ 18.6 million (£14.4 million)